Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $.001 per share
-
Shares outstanding
-
31,794,008
-
Total 13F shares
-
258,464
-
Share change
-
+258,464
-
Total reported value
-
$1,528,467
-
Price per share
-
$5.91
-
Number of holders
-
18
-
Value change
-
+$1,528,467
-
Number of buys
-
18
Institutional Holders of Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) as of Q1 2024
As of 31 Mar 2024,
Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
258,464 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., ATTICUS WEALTH MANAGEMENT, LLC, Newbridge Financial Services Group, Inc., Tower Research Capital LLC (TRC), MORGAN STANLEY, FWL INVESTMENT MANAGEMENT, LLC, and Sandy Spring Bank.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.